Perrigo Company and its partner Allergan plc announced the launch of guaifenesin 1200mg and dextromethorphan HBr 60mg extended-release tablets, the first OTC store brand equivalent to Mucinex® 1200mg DM extended-release tablets, being introduced to retail and wholesale customers. First shipments of this new store branded product have been initiated and represent a first-to-market accomplishment for Perrigo and Allergan.
These products are packaged and marketed as store brands or retailer ‘own label’ brands and provide consumers a high-quality, value alternative to the Mucinex® 1200mg DM extended-release product.
Mucinex® 1200mg DM extended-release tablets (guaifenesin 1200mg and dextromethorphan HBr 60mg extended-release tablets) are indicated to control coughs and to break up mucus, making coughs more productive. The Mucinex® 1200mg DM extended-release product produced sales of approximately $108 million through food, drug and mass merchants during the last twelve months.
Perrigo’s CEO John T. Hendrickson stated, “This is another great example of the Perrigo and Allergan teams continuing to leverage their unique capabilities in providing U.S. consumers greater savings and access to key new store brand OTC products. These new store brand products, which are equivalent to the Mucinex® brand, are an important offering to our customers as they deliver the first high-quality, value alternative available in the marketplace. Allergan has been an excellent partner in developing this range of new store brand guaifenesin ER products and we look forward to launching the remaining Mucinex® equivalent products for the store brand market throughout the balance of this year.”
“Today’s launch adds to the record of success we have had in bringing together Allergan’s leadership in generic product development with Perrigo’s strength in marketing OTC and store brand products to deliver high-quality, affordable medicines for patients around the world,” said Robert Stewart, Allergan’s Executive Vice President & President, Generics and Global Operations. “We look forward to our continued efforts to bring additional formulations that are equivalent to the Mucinex® family of products forward for the patients and customers that we serve.”
Filed Under: Drug Discovery